Patient Resources

About our Sponsor
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping patients and clinicians first. Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes.
Featured Events
- 2023 American Academy of Dermatology, March 17 – 21
- Resident Networking Event – RSVP Now
- Date: Saturday, March 18th
- Time: 6:30pm – 9:30pm
- Location: Gordon Biersch
Visit Castle Biosciences at the Following Events
- 2023 Winter Clinical Dermatology Conference, January 13-18
- Maui Derm Hawaii 2023, January 23-27
- South Beach Symposium, February 9-12
- Winter Clinical Miami, February 17-19
- Masterclasses in Dermatology, February 23-26
- USCAP 112th Annual Meeting, March 11-16
- 26th Joint Meeting of the International Society of Dermatopathology, March 15-16
Attending any of these events? Let us know!
Our Products

Provides comprehensive, personalized, genomic tumor information to guide management for patients with cutaneous melanoma
Highlights
- The first melanoma prognostic test, strongly evidenced with over 35 peer-reviewed publications and more than 9,000 patients studied
- The most comprehensive result, integrating tumor biology and clinicopathologic features to answer likelihood of a positive sentinel lymph node and risk of recurrence for patients with melanoma
- The only melanoma prognostic test shown to be associated with improved patient survival
Highlights
- Provides increased confidence and clarity for dermatopathologists and dermatologists in both diagnosis and patient management decisions
- Included in three national guidelines as an ancillary test option for facilitating a more definitive diagnosis
- Peer-reviewed publications support clinical validity and utility

Identifies the risk of metastasis in patients with squamous cell carcinoma (SCC) and one or more risk factors
Highlights
- Delivers prognostic precision as a significant predictor of metastasis and the strongest predictor of risk, compared to traditional clinical and pathological factors
- Provides unique, complementary information for SCC management to better inform choices about treatment and follow-up care
- Supported by 12 peer-reviewed publications with proven clinical validity and utility
Highlights
- The standard of care for prognosis of newly diagnosed uveal melanoma in the National Comprehensive Cancer Network (NCCN) Guidelines
- Used by 90% of U.S. ocular oncology institutions to help physicians optimize patient management based on metastatic risk
- Supported by more than 20 peer-reviewed publications with proven clinical validity and utility